Rosacea—primary care treatment pathway
Read this summary and then ‘Test and reflect’ using our multiple-choice questions.
Earn 0.5 CPD credits for reading the summary and an additional 0.5 CPD credits for completing the multiple-choice questions.
What is rosacea?
- Rosacea is a chronic disorder of the facial skin characterised by redness, particularly of the convexities—cheeks, chin, and forehead sparing the peri-ocular skin
- Flushing is common and tends to be prolonged and can be uncomfortable and embarrassing. This is often triggered by temperature change, exercise, food, emotional stimuli, and alcohol. In time telangiectasia can develop
- Some patients develop acne-like papules and pustules, but comedones are absent
- Eye symptoms are common including dryness, grittiness, blepharitis, and redness
- Rosacea can be seen in all skin types but is more common in fair skin. It affects both sexes and tends to occur in mid-life
- A subset of patients develop thickening of the facial tissues, particularly of the nose (rhinophyma) but this is relatively uncommon and very rare in women
Important information about treatments
- Treatment is often required because avoiding triggers can be difficult for patients. Use of high factor broad spectrum sunblock (sun protection factor ≥30) is recommended
- Light emollients and camouflage skin care products are beneficial. Topical steroids can exacerbate rosacea and should be avoided
- Treatment options are directed by the predominant type of rosacea. Flushing and fixed erythema can be helped by topical brimonidine, intense pulsed light (IPL), or pulsed dye laser (PDL). More raised/ inflammatory changes (i.e. papules and pustules) can be treated with topical agents (ivermectin, azelaic acid, or metronidazole gels or creams), or oral antibiotics)
- Our guidance has been developed to be mindful of the growing concerns about antibiotic resistance. If possible, the use of long-term antibiotics should be avoided
- For futher information on treatment options and rosacea subsets, please refer to the full guideline at www.pcds.org.uk/ee/images/uploads/general/Rosacea-Guidelines-FINAL.pdf
- Seborrhoeic dermatitis (may co-exist); the patient will usually have history of dandruff, dryness, and scale in the naso-labial folds, medial eyebrow, and ear
- Acne vulgaris; when presenting with greasiness, comedones and lack of background erythema
- Periorificial dermatitis; typically seen in young women, can be acneiform or eczematous around the mouth and/or eyes
- Keratosis pilaris rubra; fixed redness of cheeks since childhood with follicular erythema and scale on upper arms and thighs
|Product||Flushing and fixed erythema||Inflammatory papules and pustules||Ocular||Protocol and comments*|
|Ivermectin cream1%||+++||Well tolerated, once daily, greater efficacy than metronidazole and no concerns with antibiotic resistance|
|Azelaic acid gel||++||Effective twice daily, may cause irritation and no concerns with antibiotic resistance|
|Metronidazole gel or cream 0.75%||+||Twice daily, less effective than ivermectin|
|Brimonidine gel 0.33%||++||Effective and fast-acting vasoconstrictor, patients should be warned about the possibility of rebound flush which can limit usage|
|Eye lubricants||+++||Lid hygiene and warm eye compresses also important|
|Doxycycline MR 40 mg||+++||Once daily. Fewer side-effects and equivalent efficacy as full dose (100mg). Sub-microbial dose reduces risk of antibiotic resistance compared with other antibiotics|
|Doxycycline 100mg and lymecycline 408mg capules||++||++||Less expensive, more side-effects. Well tolerated, once daily|
|Oxytetracycline 250–500 mg||+||+||Twice daily, avoid taking with meals|
|Erythromycin/ clarithromycin 250–500 mg||+||Twice daily, useful in pregnancy|
|Isotretinoin||++||Useful in secondary care for resistant cases|
|Intense pulsed light (IPL)||+++||Limited NHS availability|
|Pulsed dye laser (PDL)||++||Limited NHS availability and causes significant bruising|
|++||Up to three times daily, improves flushing in some patients|
|+||Up to three times daily|
|Carvedilol 3.125–6.25 mg||+||Up to three times a day|
|+++ = strong recommendation
++ = moderate recommendation
+ = low recommendation.
* These comments are the opinions of the contributors, reviewed by the PCDS Executive Committee and do not consider NHS costs and local prescribing restrictions, if any.
Practical advice and further information resources for doctors and patients
- Inflammatory rosacea is highly amenable to treatment and patients should be advised that whilst a chronic condition that cannot be cured, it can be very well controlled. Long-term treatment is generally advisable to minimise the risk of progression of the disease
- Patients may initially require a combination of topical and systemic treatment, but ideally managed on topical treatments in the longer term. If significant improvement is not experienced at two months, patients should be encouraged to seek further medical advice
- Patients should be reassured that alcohol does not cause rosacea, although it may induce flushing
- We would encourage regular reviews to ensure unnecessary use of antibiotics is avoided
Consider referral if:
- Severe psychological distress
- Not responding to treatment
- Patient might benefit from IPL/PDL
Useful sources of information
- PCDS: www.pcds.org.uk
- Cochrane review: onlinelibrary.wiley.com/doi/10.1002/14651858.CD003262.pub5/abstract
- BAD patient leaflets: www.bad.org.uk/for-the-public/patient-information-leaflets
|Now Test and Reflect: view our multiple choice questions|
Primary Care Dermatology Society. Rosacea—primary care treatment pathway.
First included: August 2016.
Read the Guidelines in Practice article Rosacea: newer treatments can avoid antibiotics for more information on implementing the PCDS Rosacea—primary care treatment pathway